Abstract: The present invention relates to pharmaceutical compositions of ACE2 Fc fusion proteins and therapeutic uses thereof, in particular in the treatment of infections with SARS-CoV-2.

Abstract: The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant.

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.

Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.

Abstract: The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided.

Abstract: The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis.

Abstract: The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase.

Abstract: The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided.

Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.

Abstract: The present invention relates to a spinal nucleus pulposus implant for use in the treatment of the intervertebral disc and in particular, to the use of a CD-RAP protein therefore.

Abstract: Embodiments of a medical hand-grip element for injection of a substance from an ampoule, comprise a drive device for driving the ampoule and the injection needle, a delivery device for delivering the medicinal substance out of the ampoule and a coupling device for rotationally fixed coupling of the ampoule with the injection needle and for preventing a relative movement between the ampoule and the injection needle is disclosed. Embodiments of injection systems, injection units, injection needles and handling methods for them are also disclosed in which the risk of injury and contamination for the user is reduced by providing approaches for covering the ends of the cannulas of the injection needles during a number of handling steps.

Abstract: The present invention relates to a spinal nucleus pulposus implant for use in the treatment of the intervertebral disc and in particular, to the use of a CD-RAP protein therefore.

Abstract: The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase.

Abstract: Embodiments of a medical hand-grip element for injection of a substance from an ampoule, comprise a drive device for driving the ampoule and the injection needle, a delivery device for delivering the medicinal substance out of the ampoule and a coupling device for rotationally fixed coupling of the ampoule with the injection needle and for preventing a relative movement between the ampoule and the injection needle is disclosed. Embodiments of injection systems, injection units, injection needles and handling methods for them are also disclosed in which the risk of injury and contamination for the user is reduced by providing approaches for covering the ends of the cannulas of the injection needles during a number of handling steps.